

Supplemental Material

Multiple Inflammatory Biomarkers in Relation to Cardiovascular Events and Mortality in the Community

Renate B. Schnabel, MD, MSc; Xiaoyan Yin, PhD; Martin G. Larson, ScD;
Jennifer F. Yamamoto, MS; João D. Fontes, MD; Sekar Kathiresan, MD; Jian Rong, PhD;
Daniel Levy, MD; John F. Keaney, Jr., MD; Thomas J. Wang, MD; Joanne M. Murabito, MD;
Ramachandran S. Vasan, MD; Emelia J. Benjamin, MD, ScM

Table of Contents for Electronic Supplement

Supplementary Table I	Baseline Characteristics of the Study Sample by exclusion
Supplementary Table II.	Multivariable-Adjusted Cox Proportional Hazards Regression Models Examining Each Circulating Inflammatory Biomarker Separately in Relation to CVD
Supplementary Table III	Multivariable-Adjusted Cox Proportional Hazards Regression Models Examining Each Circulating Inflammatory Biomarker Separately in Relation to Overall Mortality
Supplementary Figure I.	Sex-specific adjusted Survival Curves by Tertile of the Biomarker Score Incorporating the Top Two Inflammatory Markers

Inflammatory biomarkers and cardiovascular outcome and mortality

Supplementary Table I. Baseline Characteristics of the Study Sample by Exclusion

	Analyzed N=3035)	Excluded N=290
Age, years	61±9	61±9
Women, %	1623 (53)	157(54)
Cigarette smoking, %	398 (13)	38(13)
Body mass index, kg/m ²	28.1±5.3	28.6±5.8
Systolic blood pressure, mm Hg	127±19	127±20
Diabetes, %	400 (13)	45 (16)
Total/high density lipoprotein cholesterol	4.1±1.3	4.1±1.4
Hypertension treatment, %	1028 (34)	97 (34)
Lipid treatment, %	622 (20)	62 (21)
Aspirin ≥3 per week, %	963 (32)	92 (32)
Hormone replacement therapy, %	499 (16)	53 (18)
Prevalent cardiovascular disease, %	208 (7)	30 (10)

Data are presented as mean±SD for continuous variables and n (percentage) for dichotomous variables.

Inflammatory biomarkers and cardiovascular outcome and mortality

Supplementary Table II. Multivariable-Adjusted Cox Proportional Hazards Regression Models Examining Each Circulating Inflammatory Biomarker Separately in Relation to CVD

Variable	Hazard Ratio	95% Confidence Interval		Nominal P-Value
CD40 ligand	0.92	0.80	1.04	0.18
CRP	1.21	1.06	1.39	0.006
Fibrinogen	1.18	1.03	1.36	0.02
Intercellular adhesion molecule-1	1.12	1.00	1.27	0.054
Interleukin-6	1.16	1.01	1.32	0.03
Lipoprotein-associated phospholipase A2				
Activity	1.05	0.90	1.22	0.55
Mass	0.99	0.87	1.12	0.82
Monocyte chemoattractant protein-1	1.09	0.95	1.24	0.22
Myeloperoxidase	1.01	0.89	1.15	0.84
P-selectin	0.97	0.85	1.10	0.64
Tumor necrosis factor receptor II	1.19	1.04	1.35	0.009

Hazard ratios, per one standard deviation increase in ln-biomarker concentration, are adjusted for age, sex, smoking, systolic blood pressure, hypertension treatment, total/HDL cholesterol, body mass index, and diabetes.

Inflammatory biomarkers and cardiovascular outcome and mortality

Supplementary Table III. Multivariable-Adjusted Cox Proportional Hazards Regression Models Examining Each Circulating Inflammatory Biomarker Separately in Relation to Overall Mortality

Variable	Mean±SD Ln Biomarker	Hazard Ratio	95% Confidence Interval		Nominal P-Value
CD40 ligand	0.41±1.23	1.00	0.90	1.12	0.97
CRP	0.82±1.12	1.32	1.18	1.48	<0.0001
Fibrinogen	5.92±0.19	1.15	1.03	1.29	0.02
Intercellular adhesion molecule-1	5.52±0.25	1.41	1.29	1.54	<0.0001
Interleukin-6	1.07±0.71	1.41	1.28	1.55	<0.0001
Lipoprotein-associated phospholipase A2					
Activity	4.93±0.25	1.16	1.01	1.32	0.03
Mass	5.65±0.32	1.07	0.96	1.19	0.20
Monocyte chemoattractant protein-1	5.74±0.34	1.03	0.92	1.15	0.63
Myeloperoxidase	3.71±0.57	1.02	0.91	1.13	0.78
P-selectin	3.57±0.37	1.10	0.99	1.23	0.08
Tumor necrosis factor receptor II	7.62±0.31	1.53	1.38	1.70	<0.0001


Inflammatory biomarker concentrations are natural log-transformed.

Hazard ratios, per one standard deviation increase in ln-biomarker concentration, are adjusted for age, sex, smoking, systolic blood pressure, total/HDL cholesterol, hypertension treatment, body mass index, diabetes, and prevalent major CVD (see text for definitions).

Inflammatory biomarkers and cardiovascular outcome and mortality

Supplementary Figure I. Sex-specific adjusted survival curves by tertile of the biomarker score incorporating the top two inflammatory markers (CRP and TNFR1I) for men (A) and women (B). The numbers of participants at risk are displayed below the figure.

A.



Inflammatory biomarkers and cardiovascular outcome and mortality

B.

